Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin

Pediatric Blood and Cancer

Volumn 49, Issue 1, 2007, Pages 103-104

  Ayas, M ^a   Al Musa, A ^a   Al Jefri, A ^a   Al Seraihi, A ^a   Al Mahr, M ^a   Rifai, S ^a   El Solh, H ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Anti thymocyte globulins; Dyskeratosis congenita; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; DRUG TOLERABILITY; DYSKERATOSIS CONGENITA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTILYMPHOCYTE SERUM; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DYSKERATOSIS CONGENITA; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34249792115     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20696     Document Type: Article

References (10)

1. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000;110:768-779.
2. Knight S, Vulliamy T, Copplestone A, et al. Dyskeratosis congenita registry: Identification of new features. Br J Haematol 1998;103: 990-1006.
3. Coulthard S, Chase A, Pickard J, et al. Chromosome breakage analysis in dyskeratosis congenita peripheral blood lymphocytes Br J Haematol 1998;102:1162-1164.
4. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999;402:551-555.
5. Langston AA, Sanders J, Deeg HJ, et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996;92:758-765.
6. Yabe M, Yabe H, Hattori K, et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997;19: 389-392.
7. Rocha V, Devergie A, Socie G, et al. Unusual complications after bone marrow transplantation for Dyskeratosis congenita. Br J Haematol 1998;103:243-248.
8. Ayas M, Al-Jefri A, Al-Mahr M, et al. Stem Cell Transplantation for patients with Fanconi Anemia with low dose Cyclophosphamide and AntiThymocyte Globulins without the use of Radiation Therapy. Bone Marrow Transplant 2005;35:463-466.
9. Dror Y, Freedman MH, Leaker M, et al. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 2003; 31:847-850.
10. Gungor T, Corbacioglu S, Storb R, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of dyskeratosis congenita. Bone Marrow Transplant 2003;31:407-410.